AI assistant
Sending…
Humacyte, Inc. — Director's Dealing 2023
Oct 10, 2023
33410_dirs_2023-10-10_e905e396-4aab-4f9b-b77d-59be56ad3159.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Humacyte, Inc. (HUMA)
CIK: 0001818382
Period of Report: 2023-10-10
Reporting Person: Niklason Laura E (Director, President, CEO and Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2023-10-10 | Common Stock | M | 114420 | $1.19 | Acquired | 1384660 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2023-10-10 | Stock Options (right to buy) | $1.19 | M | 114420 | Disposed | 2023-11-23 | Common Stock (114420) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 6191140 | Indirect |
| Common Stock | 510161 | Indirect |
More from Humacyte, Inc.
Share Issue/Capital Change
2026
May 14
Regulatory Filings
2026
Apr 24
Major Shareholding Notification
2026
Mar 24
Regulatory Filings
2026
Mar 19
Regulatory Filings
2026
Mar 19
Major Shareholding Notification
2026
Jan 9
Capital/Financing Update
2025
Dec 16
Capital/Financing Update
2025
Dec 16
Capital/Financing Update
2025
Dec 15
Regulatory Filings
2025
Dec 15